Evaxion Biotech A/S (NASDAQ:EVAX) Earns “Buy” Rating from HC Wainwright

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $14.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 449.02% from the stock’s previous close.

Separately, Lake Street Capital lowered their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th.

Evaxion Biotech A/S Stock Performance

NASDAQ:EVAX opened at $2.55 on Thursday. Evaxion Biotech A/S has a 52-week low of $2.22 and a 52-week high of $22.50. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. The company has a market cap of $2.98 million, a price-to-earnings ratio of -1.76 and a beta of -0.28. The firm’s 50-day moving average is $3.78 and its 200-day moving average is $9.71.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new position in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S at the end of the most recent quarter. 11.04% of the stock is currently owned by institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.